Schizophrenia - Revisiting symptom dimensions in schizophrenia with exploratory graph analysis

Komppanianpäällikön mukaan droonit eivät tee panssarijoukoista hyödyttömiä.

MapLight Therapeutics (Nasdaq: MPLT) reported second quarter 2026 results and a business update, highlighting positive topline data from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia. The study met its primary endpoint, showing a statistically significant and clinically meaningful PANSS total score reduction at Week 5 versus placebo at the 210/3 mg twice-daily dose, plus improvements on prespecified cognitive and key secondary endpoints, with a generally well-tolerated safety profile. MapLight plans an End-of-Phase 2 FDA meeting and a Phase 3 ZEPHYR-2 trial, with topline results expected in 2028.ML-007C-MA is also in the Phase 2 VISTA trial for Alzheimer’s disease psychosis, which has FDA Fast Track designation and topline data expected in the second half of 2027. The company reported Phase 2 IRIS results for ML-004 in autism spectrum disorder; the trial did not meet its primary endpoint, although a prespecified adolescent subgroup showed clinically meaningful improvements in irritability. MapLight ended the quarter with $351.3 million in cash, cash equivalents and investments and, together with a recent $150 million private placement, expects to fund ML-007C-MA through 2028. Quarterly R&D expenses were $53.4 million, G&A expenses were $10.1 million, and net loss was $60.2 million, all higher than the prior-year period, as the company focuses resources on advancing ML-007C-MA and pauses preclinical and discovery-stage programs.

The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to placebo at Week 5 with an effect size of 0.37 (LS mean difference vs PBO -4.5, p=0.015) Cognitive

KarXT – xanomeline plus trospium – shows significant PANSS improvements over placebo.

Provides a 'shiny' web application to map scores from clinical instruments (PANSS, SQLS, WHODAS 2.0, PHQ-8, EQ-5D-5L) to preference-based EQ-5D-5L health utility values using validated regression-based and beta-mixture mapping algorithms developed from Singapore population studies. Intended for use in health economic evaluations and cost-utility analyses. Methods are based on: Abdin et al. (2019) &lt;<a href="https://doi.org/10.1007%2Fs11136-018-2037-7" target="_top">doi:10.1007/s11136-018-2037-7</a>&gt;, Seow et al. (2023) &lt;<a href="https://doi.org/10.1080%2F14737167.2023.2215430" target="_top">doi:10.1080/14737167.2023.2215430</a>&gt;, Abdin et al. (2021) &lt;<a href="https://doi.org/10.1186%2Fs12888-021-03463-0" target="_top">doi:10.1186/s12888-021-03463-0</a>&gt;, Abdin et al. (2024) &lt;<a href="https://doi.org/10.1080%2F14737167.2024.2376100" target="_top">doi:10.1080/14737167.2024.2376100</a>&gt;.

Provides a 'shiny' web application to map scores from clinical instruments (PANSS, SQLS, WHODAS 2.0, PHQ-8, EQ-5D-5L) to preference-based EQ-5D-5L health utility values using validated regression-based and beta-mixture mapping algorithms developed from Singapore population studies. Intended for use in health economic evaluations and cost-utility analyses. Methods are based on: Abdin et al. (2019) &lt;<a href="https://doi.org/10.1007%2Fs11136-018-2037-7" target="_top">doi:10.1007/s11136-018-2037-7</a>&gt;, Seow et al. (2023) &lt;<a href="https://doi.org/10.1080%2F14737167.2023.2215430" target="_top">doi:10.1080/14737167.2023.2215430</a>&gt;, Abdin et al. (2021) &lt;<a href="https://doi.org/10.1186%2Fs12888-021-03463-0" target="_top">doi:10.1186/s12888-021-03463-0</a>&gt;, Abdin et al. (2024) &lt;<a href="https://doi.org/10.1080%2F14737167.2024.2376100" target="_top">doi:10.1080/14737167.2024.2376100</a>&gt;.